自身免疫性艾迪生病的临床与免疫学特征:瑞典全国多中心研究
该研究为横断面人群研究,纳入瑞典艾迪生登记库2008至2014年660例自身免疫性艾迪生病患者,分析自身免疫合并症、替代治疗、自身抗体谱及心血管危险因素,并与北部瑞典MONICA调查的3594名对照比较。83%患者21-羟化酶自身抗体阳性,62%合并至少一种自身免疫病,女性更常见;患者体重指数和高血压患病率低于对照,但较高的氢化可的松等效剂量与高血压发生率较高相关。
要点
- 83%患者21-羟化酶自身抗体阳性,62%合并至少一种自身免疫病,女性更常见(P < 0.0001)。
- 患者体重指数(P < 0.0001)和高血压患病率(P = 0.027)低于对照。
- 较高的氢化可的松等效剂量与高血压发生率较高相关(P = 0.046)。
核心结论
- 需要仔细监测自身免疫性艾迪生病患者以发现相关自身免疫病。
- 当代瑞典自身免疫性艾迪生病患者超重、高血压、2型糖尿病或高脂血症的患病率未增加。
- 较高的糖皮质激素替代剂量可能是高血压的危险因素。
研究设计与样本
- 横断面人群研究,纳入瑞典艾迪生登记库2008至2014年660例自身免疫性艾迪生病患者。
- 分析心血管危险因素时,以北部瑞典MONICA(心血管疾病趋势和决定因素监测)人群调查的3594名个体为对照。
- 检测针对13种自身抗原的自身抗体。
主要发现
- 21-羟化酶自身抗体阳性患者比例为83%。
- 62%患者合并至少一种相关自身免疫病,女性更常共存(P < 0.0001)。
- 与对照相比,患者体重指数较低(P < 0.0001),高血压患病率较低(P = 0.027)。
- 89%患者使用常规氢化可的松片,平均剂量为28.1 ± 8.5 mg/d。
- 按体表面积标准化的平均氢化可的松等效剂量为14.8 ± 4.4 mg/m2/d。
临床怎么用
- 作者认为需要仔细监测自身免疫性艾迪生病患者以发现相关自身免疫病。
- 作者指出较高的糖皮质激素替代剂量可能是高血压的危险因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Studies of the clinical and immunological features of autoimmune Addison disease (AAD) are needed to understand the disease burden and increased mortality. OBJECTIVE: To provide upgraded data on autoimmune comorbidities, replacement therapy, autoantibody profiles, and cardiovascular risk factors. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional, population-based study that included 660 AAD patients from the Swedish Addison Registry (2008-2014). When analyzing the cardiovascular risk factors, 3594 individuals from the population-based survey in Northern Sweden, MONICA (monitoring of trends and determinants of cardiovascular disease), served as controls. MAIN OUTCOME MEASURES: The endpoints were the prevalence of autoimmune comorbidities and cardiovascular risk factors. Autoantibodies against 13 autoantigens were determined. RESULTS: The proportion of 21-hydroxylase autoantibody-positive patients was 83%, and 62% of patients had ≥1 associated autoimmune diseases, more frequently coexisting in females (P < 0.0001). AAD patients had a lower body mass index (P < 0.0001) and prevalence of hypertension (P = 0.027) compared with controls. Conventional hydrocortisone tablets were used by 89% of the patients, with a mean dose of 28.1 ± 8.5 mg/d. The mean hydrocortisone equivalent dose normalized to the body surface was 14.8 ± 4.4 mg/m2/d. A greater hydrocortisone equivalent dose was associated with a greater incidence of hypertension (P = 0.046). CONCLUSIONS: Careful monitoring of AAD patients is warranted to detect associated autoimmune diseases. Contemporary Swedish AAD patients did not have an increased prevalence of overweight, hypertension, type 2 diabetes mellitus, or hyperlipidemia. However, high glucocorticoid replacement doses could be a risk factor for hypertension.
引用
- Dalin F, Nordling Eriksson G, Dahlqvist P, et al. Clinical and Immunological Characteristics of Autoimmune Addison Disease: A Nationwide Swedish Multicenter Study. J Clin Endocrinol Metab. 2017. PMID: 27870550. doi:10.1210/jc.2016-2522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。